A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection

Biomaterials

Volumn 35, Issue 9, 2014, Pages 3110-3120

  Han, Lu ^a,b   Zhao, Jing ^b,c   Liu, Juan ^b   Duan, Xiang Lin ^c   Li, Lu Hai ^a   Wei, Xian Fu ^a   Wei, Yen ^a,d   Liang, Xing Jie ^b  

^a BEIJING INSTITUTE OF GRAPHIC COMMUNICATION   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c HEBEI NORMAL UNIVERSITY   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

EGFP p53 plasmid; PEI PAH Cit AuNP CS nanoparticles; Prostate cancer; Universality

Indexed keywords

EGFP-P53 PLASMID; PEI/PAH-CIT/AUNP-CS NANOPARTICLES; PROSTATE CANCER; UNIVERSALITY;

BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; CITRACONIC ANHYDRIDES; GOLD; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MALE; METAL NANOPARTICLES; MICROSCOPY, FLUORESCENCE; PLASMIDS; POLYAMINES; POLYETHYLENEIMINE; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894947689     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.048     Document Type: Article

References (47)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA-Cancer J Clin 2011, 61:69-90.
2. Chhikara M., Huang H.X., Vlachaki M.T., Zhu X.H., Teh B., Chiu K.J., et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001, 3:536-542.
3. Kochanek S., Gansbacher B. Prostate cancer gene therapy: attempts to innovate. Hum Gene Ther 2010, 21:797-812.
4. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
5. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008, 126:187-204.
6. Veiseh O., Kievit F.M., Gunn J.W., Ratner B.D., Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 2009, 30:649-657.
7. Freytag S.O., Stricker H., Movsas B., Kim J.H. Prostate cancer gene therapy clinical trials. Mol Ther 2007, 15:1042-1052.
8. Kamei K., Mukai Y., Kojima H., Yoshikawa T., Yoshikawa M., Kiyohara G., et al. Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials 2009, 30:1809-1814.
9. Steiner M.S., Anthony C.T., Lu Y., Holt J.T. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998, 9:747-755.
10. Pantuck A.J., Matherly J., Zisman A., Nguyen D., Berger F., Gambhir S.S., et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther 2002, 13:777-789.
11. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005, 16:1016-1027.
12. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-294.
13. Hollstein M., Rice M., Greenblatt T., Soussi T., Fuchs R., Sørlie T., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994, 22:3551-3555.
14. Seki M., Iwakawa J., Cheng H., Cheng P.W. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002, 13:761-773.
15. Borner M.M., Myers C.E., Sartor O., Sei Y., Toko T., Trepel J.B., et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995, 55:2122-2128.
16. De Vrij J., Willemsen R.A., Lindholm L., Hoeben R.C., Consortium G. Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther 2010, 21:795-805.
17. Samanta S., Sistla R., Chaudhuri A. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials 2010, 31:1787-1797.
18. Zeng X., Sun Y.X., Qu W., Zhang X.Z., Zhuo R.X. Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection. Biomaterials 2010, 31:4771-4780.
19. Han L., Zhao J., Zhang X., Cao W.P., Hu X.X., Zou G.Z., et al. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility. ACS Nano 2012, 6:7340-7351.
20. Bhumkar D.R., Joshi H.M., Sastry M., Pokharkar V.B. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 2007, 24:1415-1426.
21. Link S., El-Sayed M.A. Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver nanodots and nanorods. J Phys Chem B 1999, 103:8410-8426.
22. Zhang X., Chen H., Zhang H. Layer-by-layer assembly: from conventional to unconventional methods. Chem Commun 2007, 14:1395-1405.
23. Decher G., Hong J.D. Buildup of ultrathin multilayer films by a self-assembly process, 1 consecutive adsorption of anionic and cationic bipolar amphiphiles on charged surfaces. Macromol Symp 1991, 46:321-327.
24. Becker A.L., Johnston A.P.R., Caruso F. Layer-by-layer-assembled capsules and films for therapeutic delivery. Small 2010, 6:1836-1852.
25. Pissuwan D., Niidome T., Cortie M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011, 149:65-71.
26. Li P., Li D., Zhang L.X., Li G.P., Wang E.K. Cationic lipid bilayer coated gold nanoparticles-mediated transfection of mammalian cells. Biomaterials 2008, 29:3617-3624.
27. Lee S.K., Han M.S., Asokan S., Tung C.H. Effective gene silencing by multilayered siRNA-coated gold nanoparticles. Small 2011, 7:364-370.
28. Guo S.T., Huang Y.Y., Jiang Q., Sun Y., Deng L.D., Liang Z.C., et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano 2010, 4:5505-5511.
29. Numata K., Subramanian B., Currie H.A. Bioengineered silk protein-based gene delivery systems. Biomaterials 2009, 30:5775-5784.
30. Panté N., Kann M. Nuclear pore complex is able to transport macromolecules with diameters of 39 nm. Mol Biol Cell 2002, 13:425-434.
31. Brunner S., Sauer T., Carotta S., Cotton M., Saltik M., Wagner E. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther 2000, 7:401-407.
32. Thomas M., Klibanov A.M. Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A 2003, 100:9138-9143.
33. Thomas M., Klibanov A.M. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A 2002, 99:14640-14645.
34. Hu Q.D., Fan H., Ping Y., Liang W.Q., Tang G.P., Li J. Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug. Chem Commun 2011, 47:5572-5574.
35. Guillem V.M., Aliño S.F. Transfection pathways of nonspecific and targeted PEI-polyplexes. Gene Ther Mol Biol 2004, 8:369-384.
36. Peng L., Liu M., Xue Y.N., Huang S.W., Zhuo R.X. Transfection and intracellular trafficking characteristics for poly(amidoamine)s with pendant primary amine in the delivery of plasmid DNA to bone marrow stromal cells. Biomaterials 2009, 30:5825-5833.
37. Wachter J., Neureiter D., Alinger B., Pichler M., Fuereder J., Oberdanner C., et al. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci 2012, 8:15-29.
38. Schuler M., Bossy-Wetzel E., Goldstein J.C., Fitzgerald P., Green D.R. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 2000, 275:7337-7342.
39. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
40. Toshiyuki M., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
41. Landgraeber S., Toetsch M., Wedemeyer C., Saxler G., Tsokos M., Knoch F.V., et al. Over-expression of p53/BAK in aseptic loosening after total hip replacement. Biomaterials 2006, 27:3010-3020.
42. Wu Y., Mehew J.W., Heckman C.A., Arcinas M., Boxer L.M. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-251.
43. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
44. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4:327-332.
45. Jänicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273:9357-9360.
46. Mikata K., Uemura H., Ohuchi H., Ohta S., Nagashima Y., Kubota Y. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation 2. Mol Cancer Ther 2002, 1:247-252.
47. Xu L., Frederik P., Pirollo K.F., Tang W.H., Rait A., Xiang L.M., et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 2002, 13:469-481.